Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amanda Scott

Rheumatology Freehold, NJ Medical Doctor

NPI 1982043477 CMS profile 1648645

4247 Route 9 N Bldg 1, Freehold, NJ 07728

Open in the dashboard

General payments

$5,753

360 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Scott of Freehold, NJ is reported in the CMS Open Payments database as having received $5,753 across 360 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,541 92
2024 General $852 58
2023 General $1,272 81
2022 General $856 55
2021 General $627 42
2020 General $201 9
2019 General $404 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Scott
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Amanda Scott were reported at $1,541. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Amanda Scott Rheumatology median Middle half National median
2019 $404 $744 $153–$2,687 $163
2020 $201 $462 $98–$2,027 $114
2021 $627 $531 $101–$2,153 $132
2022 $856 $627 $125–$2,303 $149
2023 $1,272 $741 $145–$2,524 $160
2024 $852 $830 $166–$2,660 $164
2025 $1,541 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,291 84 payments
  2. AbbVie, Inc. $954 73 payments
  3. Janssen Biotech, Inc. $663 41 payments
  4. UCB, Inc. $490 28 payments
  5. AstraZeneca Pharmaceuticals LP $402 17 payments
  6. GlaxoSmithKline, LLC. $349 21 payments
  7. Novartis Pharmaceuticals Corporation $308 16 payments
  8. E.R. Squibb & Sons, L.L.C. $266 19 payments
  9. Lilly USA, LLC $244 14 payments
  10. Aurinia Pharma U.S., Inc. $168 10 payments
  11. Other $617 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,615 357 payments
  2. Education $138 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $599 43 payments
  2. Cimzia $455 26 payments
  3. Otezla $429 27 payments
  4. TREMFYA $429 28 payments
  5. SIMPONI ARIA $382 25 payments
  6. SAPHNELO $368 15 payments
  7. BENLYSTA $349 21 payments
  8. EVENITY $309 19 payments
  9. Prolia $303 17 payments
  10. COSENTYX $291 15 payments
  11. Other $3,056 199 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

461

Median for Internal Medicine: 777

Drug cost

$443,634

Median for Internal Medicine: $73,373

Branded share of claims

15.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tavneos Avacopan Brand 13 $206,862
Enbrel Sureclick Etanercept Brand 13 $143,724
Enbrel Mini Etanercept Brand 12 $87,194
Hydroxychloroquine Sulfate Generic 53 $2,308
Methotrexate Methotrexate Sodium Brand 32 $1,115
Duloxetine Hcl Generic 43 $493
Allopurinol Generic 46 $463
Naproxen Generic 44 $432
Prednisone Generic 103 $364
Alendronate Sodium Generic 25 $218

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$213,369

Of which drugs: $162,586

Medicare patients

162

Average age 73

Services billed

14,220

127 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Osteoporosis 54%
Diabetes 30%
Depression 27%
Ischemic heart disease 26%
COPD 18%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 18 1,560 $31,804
Injection, methylprednisolone acetate, 1 mg J1010 Office 21 593 $58

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $152
$152 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $103
$103 — —
TREMFYA
  • Janssen Biotech, Inc. $86
$86 — —
SIMPONI ARIA
  • Janssen Biotech, Inc. $76
$76 — —
SKYRIZI
  • AbbVie, Inc. $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

360 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record